Robert Zerbib
Marseille, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients.
Journal: BMJ open respiratory research
Published: November 20, 2023
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: June 22, 2022
Monalizumab: inhibiting the novel immune checkpoint NKG2A.
Journal: Journal for immunotherapy of cancer
Published: May 31, 2019
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.
Journal: Oncotarget
Published: October 05, 2017
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 06, 2015
Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 02, 2012
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
Journal: Haematologica
Published: December 03, 2011
Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.
Journal: European journal of haematology
Published: October 26, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026